Scientific References Professor Schwandt
LIST OF PUBLICATIONS
BENCH
BLOOD CELL METABOLISM
Schwandt P, Birk J, Ehrhart H
Lipide in isolierten menschlichen Leukozyten. Klin Wschr 1967; 45: 1008 – 1009.
Schwandt P, Birk J, Ehrhart H
Leukozytenlipide bei Hämoblastosen. Klin Wschr 1968; 46: 687 – 689.
Schwandt P, Birk J, Ehrhart H
Phospholipidzusammensetzung in leukämischen Leukocyten. Klin. Wschr. 1969; 47: 111 – 112.
Doerr HW, Krone W, Schwandt P
Enzymaktivitäten in Retikuloseknoten: Nachweis von Glycerokinase-Aktivität. Klin. Wschr. 1971; 49: 108 – 110.
Ehrhart H, Schwandt P
NAD, ATP and lipid contents in normal and leukemic human leukocytes, before and after cytostatic therapy. Enzyme 1972; 13: 77 – 89.
ADIPOSE TISSUE METABOLISM
LIPOLYSIS
Schwandt P, Hartmann Th, Karl HJ
Der Einfluss von Nikotinsäure und Propranolol auf die lipolytische Wirkung von Catecholaminen und Peptidhormonen in vitro. Zschr ges exper Medizin 1067; 143:79 – 84.
Schwandt P, Knedel M, Lindlbauer R
Experimentelle Untersuchungen zum Verfahren der in vitro Lipolyse. Zschr Klin Chem Klin Biochem 1968; 6: 81 – 85.
Schwandt P, Hartmann Th
Untersuchungen zur Wirkung der Nikotinsäure auf die stimulierte Lipolyse. Zschr Klin Chem Klin Biochem 1968; 6: 81 – 85.
Schwandt P, Lindlbauer R, Knedel M
Zur Wirkung von Strophantin, Nikotinsäure und kaliumfreiem Inkubationsmedium auf die durch ACTH stimulierte Lipolyse freier Fettzellen. Clin. Chim. Acta 1969; 24: 267 – 274.
Weisweiler P, Schwandt P
Untersuchungen zur lipolytischen Aktivität von TSH. Klin. Wschr. 1974: 52: 297 – 299.
Richter WO, Schwandt P
Glycerol release from incubated human adipocytes is not affected by gastrointestinal peptides. Int. J. Obes. 1985; 9: 25 – 27.
Richter WO, Schwandt P
Cholecystokinin 1-21 stimulates lipolysis in human adipose tissue. Horm. Metab Res. 1989; 21: 216 – 217.
Richter WO, Robl H, Schwandt P
Human glucagon and vasoactive intestinal polypeptide (VIP) stimulate free fatty acid release from human adipose tissue in vitro. Peptides 1989; 10: 333 – 335.
Richter WO, Jacob BG, Schwandt P
Insulin inhibits lipolytic activity and degradation of ß-lipotropin in rabbit adipose tissue. Regulatory Peptides 1990; 29: 257 – 266.
ENZYMES
Werner S, Schwandt P
Untersuchungen über die Hemmwirkung von Palmitoyl-Coenzym A auf die Glycerin-3-phosphat-Dehydrogenase in vitro. Hoppe-Seyler’s Z Physiol Chem 1969; 350: 286 – 292.
Schwandt P, Doerr HW, Krone W, Werner S
Aktivitätsbestimmung von Schlüsselenzymen im menschlichen Fettgewebe. Klin. Wschr. 1970; 48: 224 – 227.
Krone W, Doerr HW, Schwandt P
Enzymaktivitäten im Fettgewebe bei Hyperlipidämie. Klin. Wschr. 1970; 48: 503 – 504.
Schwandt P, Doerr HW, Krone W
Enzymaktivitäten im Fettgewebe. – Vergleichende Untersuchungen bei Ratte, Schwein und Mensch. Klin. Wschr. 1971; 49: 358 – 360.
Schwandt P, Hagen R
Influence of lipid lipid-lowering drug therapy on enzyme patterns in human adipose tissue.
International Congress 1973, Amsterdam, Series No. 283.
Wilkening J, Schwandt P
Alterations of the glycolytic pathway and adenine nucleotide state in livers of clofibrate treated rats
Horm Metab Res 1977; 9: 132 – 136.
Wilkening J, Wolpert F, Schwandt P
Glycolytic metabolites and adenosine triphosphate in skeletal and cardiac muscle of rats after clofibrate feeding. Biochem. Pharmacol. 1978; 27: 244 – 245.
PITUITARY HORMONES
Schwandt P, Karl HJ, Thüner J, Knedel M
Untersuchungen über eine lipolytisch wirksame Substanz aus Schweinehypophysen (Fraktion H). – Extraktion und Reinigung der lipolytischen Substanz. Z. ges. exp. Med. 1968 ; 147 : 246 – 252.
Schwandt P, Werner S, Karl HJ
Untersuchungen über biologische Wirkungen eines lipolytisch wirksamen Peptids aus Schweine-hypophysen (Fraktion H.) – I. Einfluss auf die hormonempfindliche Triglyzeridlipase. Z. ges. exp. Med. 1968; 148: 164 – 167.
Schwandt P
Über die hypophysäre Regulation des Fettstoffwechsels. Int J Clin Pharmacol. SD 1969; 57 – 62.
Schwandt P, Werner S
Untersuchungen über biologische Wirkungen eines lipolytisch wirksamen Peptids aus Schweine-hypophysen (Fraktion H.) – II. Zeitliches Verhalten von Lipiden, Glucose, Elektrolyten, Eiweis, Kreatinin und Harnstoff-N im Serum von Kaninchen. Z. ges. exp. Med. 1969; 149: 132 – 138.
Schwandt P, Werner S, Karl HJ
Untersuchungen über biologische Wirkungen eines lipolytisch wirksamen Peptids aus Schweine-hypophysen (Fraktion H.) – III. Wirkung auf Enzymaktivitäten in Fettgewebe und Leber. Z. ges. exp. Med. 1969; 149: 139 – 144.
Fateh-Moghadam A, Werner S., Eicher R, Schwandt P
Untersuchungen über biologische Wirkungen eines lipolytisch wirksamen Peptids aus Schweine-hypophysen (Fraktion H.) – IV. Immunologische Eigenschaften. Z. ges. exp. Med. 1969 ; 149 : 226 – 232.
Schwandt P, Weisweiler P, Eicher R
Vergleichende Untersuchungen über ein Lipotropin aus Humanhypophysen. Klin. Wschr. 1969; 47: 1174 – 1175.
Schwandt P, Weisweiler P, Lamerz R
Darstellung eines lipolytisch wirksamen Polypeptids (Peptid A) aus Hypophysen vom Schwein. Z. ges. exp. Med. 1971; 155: 195 – 203.
Schwandt P, Weisweiler P, Krone H, Doerr HW
Zur Wirkung eines lipodmobilisierenden Peptide aus Schweinehypophysen bei verschiedenen Spezies. Klin. Wschr. 1971; 49: 437 – 439.
Schwandt P, Weisweiler P, Pieper M, Lydtin H, Marshall M
In vivo studies in the minipig on a lipid-mobilizing polypeptide from procine pituitary glands. Res. Exp. Med 1972; 158: 246 – 250.
Müller OA, Pister W, Schwandt P, Scriba PC, Weisweiler P
Biological ACTH activity of lipid mobilizing peptide fractions from hog pituitaries. Horm Metab Res. 1973; 4: 258 – 261.
Schwandt P
Die Lipotropine. Klin. Wschr. 1974; 52: 153 – 165. (32)
Weisweiler P, Schwandt P
Biological action of the lipotrophic peptides A and B from pig pituitary glands. Acta Endocrinologica 1975; 79: 34 – 42.
Schwandt P
Pituitary lipolytic peptides. Ann Nutr Alimt. 1979; 33: 39 – 56.
Schwandt P, Richter W, Wilkening J
In vitro lipolytic activity of porcine beta-endorphin not mediated by an opiate receptor. FEBS Lett. 1979: 100: 360 – 362.
Schwandt P
Lipolytic Peptides of the Pituitary Gland. Brain and Pituitary Peptides 1980, Ferring Symp. Munich 1979; 79 – 88.
Loren I, Schwandt P, Alumets J, Hakanson R, Neureuther G, Richter WO, Sundler F
Evidence that lipolytic peptide B occurs in the ACTH/MSH-cells of the pituitary and in the brain. An immunocytochemical study of its distribution in correlations to the distribution of neurophysin. Cell Tissue Res. 1980; 205: 349 – 359.
Schwandt P, Richter WO
Purification of porcine neurophysins I and II by high performance liquid chromatography. Biochim Biophys Acta. 1980; 16; 626: 376 – 382.
Schwandt P
Lipolytic effects of ACTH and lipotrophins. Front Horm Res. 1981; 8: 107 – 121.
Richter W, Schwandt P.
Preparation of porcine neurophysin proteins by high performance liquid chromatography. J Neurochem. 1981; 36: 1279 – 1280.
Schwandt P, Richter WO, Kerscher P, Bottermann P
Beta-Lipotropin increases plasma insulin immunoreactivity. Life Sci. 1981; 29: 345 – 349.
Richter WO, Schwandt P
Mikroheterogenität der Neurophysine. Funkt. Biol. Med. 1982; 1: 140 – 147.
Schwandt P, Richter WO
Effects of pituitary peptides on fat mobilisation. Int. J. Obes. 1982; 6 Suppl. 1 : 49 – 54.
Schwandt P
The proopiocortin peptides in relation to obesity. Ric Clin Sper Med. 1983; 2 Suppl. 1: 109 – 118.
Richter WO, Schwandt P
In vitro Lipolysis of Proopiocortin Peptides. Life Sci. 1983; 33 Suppl. 1: 747 – 750.
Richter WO, Kerscher P, Schwandt P
Beta-endorphin stimulates in vivo lipolysis in the rabbit. Life Sci. 1983; 33 Suppl. 1: 743 – 746.
Richter WO, Schwandt, P
Postmortal degradation of neuropeptides in the neurohypophysis. Neuropeptides 1983; 3: 379 – 386.
Richter WO, Kerscher P, Janetschek P, Schwandt P
Metabolic effects of beta-lipotropin in vivo and in vitro in the rabbit. Central and Peripheral Endorphins: Basic and Clinical Aspects; New York 1984.
Richter WO, Kerscher P, Schwandt P
ß-lipotropin increases ketone body plasma concentration in rabbits. Neuropeptides 1984; 4: 167 – 173.
Schwandt P
Hypothalamic control of lipid metabolism. Acta Neurochirugica 1985; 75: S. 122 – 124.
Richter WO, Jacob B, Schwandt P
Degradation and lipolytic effects of beta-lipotropin are inhibited by lysosomal inhibitors. Biomedical Division – Diabetes, obesity and hyperlipidemias III. 1985; 177 – 184.
Richter WO, Schwandt P
Physiologic concentrations of beta-lipotropin stimulate lipolysis in rabbit adipocytes. Metabolism 1985; 34: 539 – 543.
Richter WO, Schwandt P
Melanotropin potentiating factor inhibits lipolytic activity of betalipotropin but not of melanocyte stimulating hormones. Neuropeptides. 1986; 7: 73 – 77.
Richter WO, Schwandt P
Lipolytic potency of proopiomelanocorticotropin peptides in vitro. Neuropeptides 1987: 9: 59 – 74.
Richter WO, Naude´ RJ, Oelofsen W, Schwandt P
In vitro lipolytic activity of beta-endorphin and its partial sequences. Endocrinology. 1987; 120: 1472 – 1476.
Ritter MM, Richter WO, Schwandt P
Increase of ß-endorphin serum levels by human corticotropin-Releasing factor does not affect beta-cell function in normalweight men. Horm. metabol. Res. 1989; 21: 383 – 386.
LIPOPROTEINS
Weisweiler P, Schwandt P
Lipid compositon of serum lipoproteins in patients with primary type IIb and type IV hyperlipoproteinemia. Atherosclerosis 1978; 31: 53 – 58.
Schwandt P, Richter WO, Weisweiler P
Separation of human C-apolipoproteins by high-performance liquid chromatography. J Chromatogr. 1981; 225: 185 – 188.
Weisweiler P, Schwandt P
Isolation of human apolipoprotein E by chromatofocusing. Clin. Chim. Acta 1982; 124: 45 – 50.
Weisweiler P, Jüngst D, Schwandt P
Quantitation of apolipoprotein E-isoforms in diabetes mellitus. Horm. metabol. Res. 1983; 15: 201.
Weisweiler P, Schwandt P
Immunonephelometric quantitation of apolipoprotein E in human serum. J. Clin. Chem. Clin. Biochem. 1983; 21: 227 – 230.
Schwandt P, Richter WO, Heinemann V, Weisweiler P
Characterization of human apolipoprotein A-I by reversed-phase high-performance liquid chromatography. J. Chromatogr. 1985; 345: 145 – 149.
Weisweiler P, Friedl C, Schwandt P
Fast protein chromatofocusing of human very-low-density lipoprotein. Biochem. Biophys. Acta 1986: 875: 48 – 51.
Ritter MM, Gewitsch J, Richter WO, Geiss HC, Wildner MW, Schwandt P
Apolipoprotein E polymorphism has no independent effect on plasma levels in lipoprotein(a). Atherosclerosis 1997; 131: 243 – 248.
Otto C., Pschierer V., Sönnichsen AC, Schwandt P, Richter WO
Postprandial hemorrheology and apolipoprotein B metabolism in patients with familial hypertriglyceridemia. Metabolism 1997; 46: 1299 – 1304.
Parhofer KG, Barrett PH, Schwandt P
Low density lipoprotein apolipoprotein B metabolism: comparison of two methods to establish kinetic parameters. Atherosclerosis 1999; 144: 159 – 166.
Parhofer KG, Barrett PH, Schwandt P
Low density lipoprotein apolipoprotein B metabolism: comparison of two methods to establish kinetic parameters. Atherosclerosis 1999; 144: 159 – 166.
Parhofer KG, Barrett PH, Demant T, Schwandt P
Acute effects of low density lipoprotein apheresis on metabolic parameters of apoliprotein B. J Lipid Res. 2000; 41: 1596 – 1603.
ANALYTICAL BIOCHEMISTRY
Neureuther G, Schwandt P, Otto J
Radioimmunoassay for porcine lipotrophic peptide B. Acta Endocrinologia 1977; 85: 291 – 299.
Schwandt P, Richter W, Morley JS
Beta-Lipotropin contains two lipolytic sequences. Neuropeptides 1981; 1: 211 – 216.
Richter WO, Schwandt P
Simultaneous separation of peptide hormones occurring in the digestive tract. Fresenius Z Anal Chem. 1982; 311: 430 – 431.
Schwandt P, Richter WO, Reuschel-Janetschek E
HPLC analysis of neurophysin proteins from neurosecretory granules. J. Neurochem. 1982; 39: 357 – 359.
Richter WO, Schwandt P
Microheterogeneous neurophysins in newly formed and aged neurosecretory granules. Neuropeptides 1983; 4: 11 – 15. (104)
Richter WO, Jacob B. Schwandt P
Molecular weight determination of peptides by high-performance gel permeation chromatography. Anal Biochem. 1983; 133: 288 – 291.
Richter WO, Schwandt P
Human neurophysins – isolation by high performance liquid chromatography from different extracts. Exp. Clin. Endocrinol. 1984; 83: 320 – 326.
Richter WO, Schwandt P
Desalting peptides by high-performance gel permeation chromatography. J. Chromatogr. 1984; 288: 212 – 214.
Richter WO, Schwandt P
Separation of neuropeptides by high performance liquid chromatography. Evaluation of different supports – analytical and preparative applications with human and porcine neurophysins, ß-lipotropin, ACTH, and ß-endorphin. J. Neurochem. 1985; 44: 1697 – 1703.
Richter WO, Jacob BG, Schwandt P
Processing of the lipid-mobilizing peptide beta-lipotropin in rabbit adipose tissue. Mol Cell Endocrinol. 1990; 71: 229 – 238.
BEDSIDE
GENERAL
Reimann R, Schwandt P
Frischer Herzinfarkt und freie Fettsäuren. Dtsch. Med. Wschr. 1971; 96: 93 – 96.
Schwandt P
Zur Prophylaxe der Arteriosklerose. Der Internist 1973; 14: 325 – 329.
Janetschek, P, Schwandt P
Synkopale Anfälle mit Schwindel und Schweißausbrüchen. Der Internist 1981; 22: 356 – 359.
Neureuther G, Luderschmidt, Schwandt P
Septischer Schock mit haemorrhagischem Exanthem. Der Internist 1983; 24: 107 – 109.
Richter WO, Schwandt P
Maulvolle Expektoration bei Malaria. Münch. med. Wschr. 1983; 125: 553 – 554.
Weisweiler P, Schwandt P
Claudicatio intermittens, koronare Herzkrankheit und Xanthome. Der Internist 1983; 24: 594 – 596.
Schwandt P
Stoffwechselkrankheiten. Münch Med Wschr. 1984; 126: 846 – 847.
Ritter MM, Richter WO, Schwandt P
Thoracoabdominal neuropathy. Arch Intern Med. 1988; 148: 1663.
Parhofer KG, Richter WO, Stiess W, Schwandt P
Akanthozytose, Minderwuchs und gestörte Tiefensensibilität bei einer 26-jährigen Patientin. Internist 1989; 30: 382 – 385.
Schwandt P
Adipositas und Lipomatose. Münch. Med. Wschr. 1989: 131(5): 57.
Assmann G, Berg A, Breithardt G, Gleichmann U, Halhuber M, Keil U, Kochsick K, Kruse-Jarres J, Lichtlen P, Schlierf G, Schwandt P, Weidemann H, Wisser H
Nationale Cholesterin-Initiative. SD Dtsch. Ärzteblatt – Ärztliche Mitteilungen 1990: 1 – 20.
Schwandt P
Gicht ohne Hyperurikämie? Dtsch. Med. Wschr. 1990; 115: 1733 – 1734.
Beuers U, Richter WO, Ritter MM, Wiebecke B, Schwandt P
Klinefelter’s syndrome and liver adenoma. J. Clin. Gastroenterol 1991; 13: 214 – 216.
Schraudolph M, Richter WO, Permanetter W, Ritter MM, Beuers U, Schwandt P
61-jährige Patientin mit Diabetes mellitus, Gewichtsverlust, Übelkeit und Erbrechen nach Resektion eines Pankreastumors. Internist 1991; 32: 229 – 234.
Schwandt P, Richter WO
Ernährungsstörungen. Innere Medizin in Praxis und Klinik 1992; Band IV: 16.1 – 16.51.
Schwandt P
History should be considered before screening. BMJ 1994; 309: 1374.
Geiss HC, Ritter MM, Richter WO, Schwandt P, Zachoval R
Low lipoprotein (a) levels during acute viral hepatitis. Hepatology 1996; 24: 1334 – 1337.
Schwandt P
Prävention statt Reparaturen. Fortschr. Med. 1996; 6: 1.
Otto C, Donner MG, Schwandt P, Richter WO
Seasonal variations of hemorheological and lipid parameters in middle-aged healthy subjects. Clin Chim Acta 1996; 256: 87 – 94.
Laubach E, Ritter MM, Giunta C, Geiss HC, Hiller E, Superti-Furga A, Schwandt P, Steinmann B
46jährige Patientin mit Blutungsneigung und Nierenarterienaneurysmata. Der Internist 1997; 38: 1225 – 1230.
Schwandt P
KHK: Fakten und Spekulationen. Fortschr. Med. 1997; 20-21: 23.
Geier A, Fürst H, Laubach E. Stäbler A, Tilling R, Müller-Höcker J, Schwandt P, Ritter MM
Somnolenz und Erbrechen bei einer Patientin nach operiertem Nebenschilddrüsen-Karzinom. Der Internist 1999; 40: 311 – 315.
Laubach E, Schwandt P
Neutral protamine Hagedorn insulin. The Lancet 2000; 355: 236.
Otto C, Richter WO, Schwandt P
Contribution of fibrinogen and lipoproteins to plasma viscosity in hypercholesterolemia and trigyceridemia: evaluation by selective depletion of low-density lipoproteins or fibrinogen. Metabolism 2000; 49: 810 – 813.
Otto C, Schwandt P
Die Frau über 50 und ihre Gesundheit – Risiko Lipoproteinstoffwechsel. Geburtsh Frauenheilk 2000; 60: M145 – M149.
Empen K, Otto C, Parhofer KG, Bosch T, Schwandt P
Heftige Bauchschmerzen bei einer 19-jährigen Patientin unter oraler Kontrazeption. Der Internist 2000; 10: 1099 – 1102.
Zachoval R, Gerbes AL, Schwandt P, Parhofer KG
Short-term effects of statin therapy in patients with hyperlipoproteinemia after liver transplantation: results of a randomized cross-over trial. J Hepatol. 2001; 35: 86 – 91.
DYSLIPOPROTEINEMIA
Schwandt P
Die Hyperlipoproteinämien: Bedeutung – Diagnose – Therapie. Der Internist 1971; 12: 481 – 487.
Schwandt P
Die sekundären Hyperlipoproteinämien. Münch. Med. Wschr. 1973; 115 Nr. 15: 644 – 649.
Weisweiler P, Schwandt P
Aktuelle Diagnostik und Therapie von Hyperlipoproteinämien. Herz/Kreisl. 1980; 12 (4): 157 – 162.
Schwandt P
Die Apolipoproteine. Klin. Wschr. 1982; 60: 637 – 649.
Schwandt P
Die Rolle der Lipoproteine in der Atherogenese. Koronare Herzkrankheit 1988; SD S. 31 – 36.
Schwandt P
Diagnostische Strategie bei Fettstoffwechselstörungen. Der Bayerische Internist 1988; 3: 2 – 5.
Sühler K, Richter WO, Schwandt P
Die invasive Therapie von Hyperlipoproteinämien. Der Bayerische Internist 1990; 6: 38 – 40.
Ritter MM, Richter WO, Schwandt P
Triglyceride – ein Risikofaktor für die koronare Herzkrankkeit? Der Bayerische Internist 1990; 6: 13 – 16.
Jacob BG, Richter WO, Schwandt P
Die medikamentöse Behandlung von Dyslipoproteinämien. Der Bayerische Internist 1990; 6: 31 – 36.
Sönnichsen AC, Richter WO, Schwandt P
Primäre und sekundäre Dyslipoproteinämien. Der Bayerische Internist 1990; 6: 17 – 22.
Schwandt P
Früherkennung von Hyperlipoproteinämien und Intervention. Nutr Dep Dis, Bibl Nutr. Dieta, 1992; 50: 19 – 27.
Ritter MM, Richter WO, Schwandt P
Sekundäre Dyslipoproteinämien. Der Internist 1992; 33: 16 – 23.
Richter WO, Schwandt P
Klassifizierung von Fettstoffwechselstörungen. Internist 1992; 33: 728 – 731.
Ritter MM, Geiss HC, Richter WO, Schwandt P
Lipoprotein (a) concentrations and phenotypes in controls and patients with hypercholesterolemia or hypertriglyceridemia. Metabolism. 1994; 43: 572 – 578.
Schwandt P, Richter WO, Sönnichsen AC
Lowering High Plasma Cholesterol Levels is not Dangerous. Arch Intern Med. 1995; 155: 985.
LDL-APHERESIS
Ritter MM, Sühler K, Richter W, Schwandt P
Short- and long-term effects of LDL-apheresis on lipoprotein (a) serum levels. Clin. Chim. Acta. 1990; 195: 9 – 16. (173)
Richter WO, Vierneisel K, Sühler K, Schwandt P
Extrakorporale LDL-Eliminationsverfahren zur Behandlung der familiären Hypercholesterinämie. Arteriosklerose – Neue Aspekte aus Zellbiologie und Molekulargenetik, Epidemiologie und Klinik. Auf der Tagung der Deutschen Gesellschaft für Arteriosklerose-Forschung. S. 92 – 97.
Richter WO, Jacob B, Ritter MM, Sühler K, Vierneisel K, Schwandt P
Treatment of severe hypercholesterolemia with heparin-induced LDL apheresis. Current Therapeutic Resarch 1992; 52: 317 – 329.
Richter WO, Jacob BG, Ritter MM, Suhler K, Vierneisel K, Schwandt P
Three-year treatment of familial heterozygous hypercholesterolemia by extracorporeal low-density lipoprotein immunoadsorption with polyclonal apolipoprotein B antibodies. Metabolism. 1993; 42; 888 – 894.
Jacob BG, Richter WO, Schwandt P
Therapy of severe familial heterozygous hypercholesterolemia by low-density lipoprotein apheresis with immunoadsorption: effects of the addition of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors to therapy. Clin. Invest. 1993; 71: 908 – 912.
Schwandt P, Richter WO
Effects of LDL apheresis on coronary heart disease. Ann. Med. Interne 1994; 145: 337 – 339.
Ritter MM, Richter WO, Schwandt P
Elimination of Lipoprotein(a) by Apheresis using Polyclonal Apo-B 100 Antibodies. Journal of Clinical Apheresis 1994; 9: 240.
Richter WO, Donner MG, Schwandt P
Short- and long-term effects on serum lipoproteins by three different te of apheresis. Artif Organs. 1996; 20(4): 311 – 317.
Donner MG, Richter WO, Schwandt P
Long term effect of LDL apheresis on coronary heart disease. Acta Angiologica 1996; 2.2: 147 – 151.
Donner MG, Richter WO, Schwandt P
Long-term follow-up of carotid atherosclerosis in patients with heterozygous familial hypercholesterolemia under LDL apheresis treatment. J Clin Apheresis. 1997; 12: 202 – 203.
Richter WO, Donner MG, Schwandt P
Elimination of islet cell antibodies and glutamic acid decarboxylase antibodies in a patient with newly diagnosed insulin-dependent diabetes mellitus. J Clin Apheresis 1997; 12: 196 – 199.
Richter WO, Donner MG, Selmaier A, Hiller E, Schwandt P
Efficacy and safety of immunoglobulin apheresis. ASAIO J. 1997; 43: 53 – 59.
Richter WO, Donner MG, Höfling B, Schwandt P
Long-term effect of low-density lipoprotein apheresis on plasma lipoproteins and coronary heart disease in native vessels and coronary bypass in severe heterozygous familial hypercholesterolemia. Metabolism 1998; 47: 863 – 868.
Geiss HC, Parhofer KG, Schwandt P
Atorvastatin compared with simvastatin in patients with severe LDL hypercholesterolaemia treated by regular LDL apheresis. J Intern Med. 1999; 245: 47 – 55.
Geiss HC, Parhofer KG, Donner MG, Schwandt P
Low density lipoprotein apheresis by membrane differential filtration (cascade filtration). Ther Apher. 1999; 3: 199 – 202.
Donner MG, Parhofer KG, Richter WO, Schwandt P
Low-density lipoprotein (LDL) oxidizability before and after LDL apheresis. Metabolism 1999; 48: 881 – 886.
Otto C, Geiss HC, Donner MG, Parhofer KG, Schwandt P
Influence of atorvastatin versus simvastatin on fibrinogen and other hemorheological parameters in patients with severe hypercholesterolemia with regular low-density lipoprotein immunoadsorption apheresis. Ther Apher. 2000; 4: 244 – 248. (272)
Parhofer KG, Geiss HC, Schwandt, P.
Efficacy of different low-density Lipoprotein apheresis methods. Ther Apher. 2000; 4: 382-385.
Schamberger BM, Geiss HC, Ritter MM, Schwandt P, Parhofer KG
Influence of LDL apheresis on LDL subtypes in patients with coronary heart disease and severe hyperlipoproteinemia. J Lipid Res. 2000; 41: 727 – 733.
Schwandt P
Lipid Apheresis: The only therapeutic option for a very small group of cardiovascular patients with high low-density Lipoprotein Cholesterol or Lipoprotein(a) Blood Concentrations. Therapeutic Apheresis and Dialysis 2003; 7 (3): 283 – 284.
Otto C, Kern P, Bambauer R, Kallert S, Schwandt P, Parhofer KG
Efficacy and Safety of a New Whole-blood Low-density Lipoprotein Apheresis System (Liposorber D) in Severe Hypercholesterolemia. International Society for Artificial Organs 2003; 27(12); 1116 – 1122.
DRUGS
Land PG, Vollmar J, Klemens UH, Löwis of menar PV, Gries FA, Koschinsky T, Huth K, Pilz E, Schlierf G, Kremer GJ, Lenhart P, Schwandt P, Hammerl H, Studlar M
Die lipidsenkende Wirkung von Phenformin bei primärer Hyperlipoproteinämie Typ IV. Dtsch. Med. Wschr. 1973; 98: 2280 – 2286.
Weisweiler P, Schwandt P
Behandlung der primären Hyperlipoproteinämie Typ IV mit verschiedenen Biguaniden. Klin.Wschr. 1976; 54: 283 – 285.
Schwandt P, Weisweiler P, Neureuther G, Wilkening J
Einfluss von Clofibrat auf Glukosetoleranz und Insulinsekretion bei Patienten mit endogener Hypertriglyceridämie. Münch. med. Wschr. 1976; 118: 351 – 354.
Schwandt P, Weisweiler P, Neureuther G, Wilkening J
Einfluss von Clofibrat auf Glukosetoleranz und Insulinsekretion bei Patienten mit endogener Hypertriglyceridämie. Münch. med. Wschr. 1976; 118: 351 – 354.
Weisweiler P, Schwandt P
Lipoproteinveränderungen unter Clofibrat bei Typ IV Hyperlipoproteinämien. Klin.Wschr. 1977; 55: 791 – 794.
Koschinsky T, Gries FA, Schwandt P, Weisweiler P, Hansen W, Nijssen FJ, Beckmann R
Therapie primärer Hyperlipoproteinämien Typ IIb und IV mit Butylbiguanid plus Clofibrat. Münch. med. Wschr. 1977; 119: 701 – 704.
Schwandt P, Weisweiler P, Neureuther G
Serum lipoprotein lipids after gemfibrozil treatment. Artery 1979; 5: 117 – 124.
Schwandt P, Weisweiler P, Neureuther G
The effect of ß-pyridycarbinol on lipoprotein lipids in primary type IIa hyperlipoproteinemia. Atherosclerosis 1979; 34: 35 – 39.
Weisweiler P, Neureuther G, Schwandt P
The effect of cholestyramine on lipoprotein lipids in patients with primary typ IIa hyperlipoproteinemia. Atherosclerosis 1979; 33: 295 – 300.
Schwandt P, Weisweiler P
The effect of D-thyroxine on lipoprotein lipids and apolipoproteins in primary type Iia- hyperlipoproteinemia. Atherosclerosis 1980; 35: 301 – 306.
Weisweiler P, Schwandt P
Lipoprotein lipids and apolipoproteins after six month’s treatment with bezafibrate. Artery 1980; 6: 402 – 408.
Schwandt P, Weisweiler P
Effect of Bezafibrate on the High-Density Lipoprotein Subfractions HDL2 and HDL3 in primary Hyperlipoproteinemia Type IV. Artery 1980; 7 (6): 464 – 470.
Weisweiler P, Schwandt P
Effects of etiroxate on low density and high density lipoproteins in hypercholesterolemic patients. Atherosclerosis 1981; 39: 45 – 49.
Schwandt P, Weisweiler P, Drosner M, Janetschek, P
Effects of bezafibrate on the composition of very low density lipoproteins in type IV hyperlipoproteinemia. Atherosclerosis. 1982; 42: 245 – 249.
Schwandt P, Richter WO, Weisweiler P, Neureuther G
Cholestyramine plus pectin in treatment of patients with familial hypercholesterolemia. Atherosclerosis 1982; 44: 379 – 383.
Weisweiler P, Merk W, Janetschek P, Schwandt P
Changes of serum lipoproteins in hypercholesterolemic subjects given fenofibrate. Atherosclerosis Cardiovasc Disease 1984; 213 – 216.
Weisweiler P, Heinemann V, Schwandt P
Serumlipoproteins and lecithin: cholesterol acyltransferase (LCAT) activity in hypercholesterolemic subjects given ß-sitosterol. Intern. J. Clin. Pharmacol. Ther. and Toxicol. 1984; 22: 204 – 206.
Weisweiler P, Merk W, Janetschek P, Schwandt P
Effect of fenofibrate on serum lipoproteins in subjects with familial hypercholesterolemia and combined hyperlipidemia. Atherosclerosis 1984; 53: 321 – 325.
Weisweiler P, Merk W, Jacob B, Schwandt P
Fenofibrate and colestipol: effects on serum and lipoprotein lipids and apolipoproteins in familial hypercholesterolemia. Eur. J. Clin. Pharmacol. 1986 ; 30 : 191 – 194.
Weisweiler P, Schwandt P
Colestipol plus fenofibrate versus synvinolin in familial hypercholesterolaemia. Lancet. 1986; 2 (8517): 1212 – 1213.
Schwandt P
Drug treatment of hypercholesterolemia. Advances in Lipoprotein and Atherosclerosis Research, diagnostics and Treatment. 7th International Dresden Lipid Symposium 1991; 98 – 103.
Richter WO, Jacob BG, Ritter MM, Schwandt P
Treatment of primary chylomicronemia due to familial hypertriglyceridemia by omega-3 fatty acids.
Metabolism. 1992; 41: 1100 – 1105.
Jacob BG, Möhrle W, Richter WO, Schwandt P
Short- and long-term effects of lovastatin and pravastatin alone and in combination with colestyramine on serum lipids, lipoproteins in primary hypercholesterolaemia. Eur. J. Clin. Pharmacol. 1992; 42: 353 – 358.
Schwandt P
Combined drug treatment of severe Hypercholesterolemia. Drugs affecting Lipid Metabolism. Medical Science Symposia Series 1993; 2: 283 – 292.
Richter WO, Schwandt P
Die Gallensäureaustauscherharze. Dtsch. Ärzteblatt – Ärztliche Mitteilungen 1993; Suppl. Heft 36: 6 – 12.
Jacob BG, Richter WO, Schwandt P
Long-Term Effects (2 year) of the HMG CoA reductase inhibitors Lovastatin and Pravastatin in combination with cholestyramine in severe primary Hypercholesterolemia.
Journal of Cardiovasc Pharmacol. 1993; 22(3): 396 – 400.
Schwandt P
Verordnung von Medikamenten zur Behandlung von Dyslipoproteinämien bei älteren Patienten. Dtsch. Ärzteblatt – Ärztliche Mitteilungen 1993; Heft 27.
Pschierer V, Richter WO, Schwandt P
Primary chylomicronemia in patients with severe familial hypertriglyceridemia responds to long-term treatment with (n-3) fatty acids. J Nutr. 1995; 125: 1490 – 1494.
Schwandt P, Richter WO
Medikamentöse Therapie der Hypercholesterinämie. Wien Klin Wochenschr. 1995; 107/18: 544 – 548.
Parhofer KG, Richter WO, Schwandt P
Drug Therapy of Severe Hypercholesterolemia in Patients with Coronary Artery Disease. Artif Organs. 1996; 20(4): 286 – 291.
Otto C, Ritter MM, Soennichsen AC, Schwandt P, Richter WO
Effects of n-3 fatty acids and fenofibrate on lipid and hemorrheological parameters in familial dysbetalipoproteinemia and familial hypertriglyceridemia. Metabolism 1996; 45: 1305 – 1311.
Otto C, Schwandt P
Gibt es Unterschiede zwischen verschiedenen Statinen? Der Internist 1998; 39: 987 – 993.
Otto C, Parhofer KG, Ritter MM, Richter WO, Schwandt P
Effects of acipimox on haemorheology and plasma lipoproteins in patients with mixed hyperlipoproteinaemia. Br J Clin Pharmacol 1998; 46: 473 – 478.
Riegger G, Abletshauser C, Ludwig M, Schwandt P, Widimsky J, Weidinger G, Welzel D
The effect of fluvastatin on cardiac events in patients with symptomatic coronary artery disease during one years of treatment. Atherosclerosis 1999; 144: 263 – 270.
Otto C, Schwandt P
Wenn Statine allein zur Lipidsenkung nicht ausreichen. Der Internist 1999; 40: 1338 – 1345.
Otto C, Schwandt P
Letter to the Editor. More on Atorvastatin and fibrinogen. Atherosclerosis 2000; 151; 591 – 592.
Laubach E, Otto C, Schwandt P
Toward better therapy of hypercholesterolemia. Arch Intern Med. 2000; 160: 2685 – 2686.
Frost RJ, Otto C, Geiss HC, Schwandt P, Parhofer KG
Effects of atorvastatin versus fenofibrate on lipoprotein profiles, low-density lipoprotein Subfraction distribution, and hemorheologic parameters in type 2 diabetes mellitus with mixed hyperlipoproteinemia. Am J Cardiol. 2001; 87: 44 – 48.
Geiss HC, Otto C, Schwandt P, Parhofer KG
Effect of atorvastatin on low-density lipoprotein subtypes in patient with different forms of hyperlipoproteinemia and control subjects. Metabolism 2001; 50: 983 – 988.
Döser S, März W, Reinecke MF, Ringleb P, Schultz A, Schwandt P, Becker HJ, Bönner G, Buerke M, Diener HC, Gohlke H, Keil U, Ringelstein EB, Steinmetz A, Gladisch R, Wehling M
Empfehlungen zur Statintherapie im Alter. Der Internist 2004; 45: 1053 – 1062.
ADIPOSITY
Weisweiler P, Schwandt P
Glukosetoleranz, Insulin und Lipide nach einwöchiger Fenfluramingabe bei Übergewichtigen. Münch. med. Wschr. 1975; 117: 1925 – 1928.
Fateh-Moghadam A, Schwandt P, Sandel P, Vogt W, Kling S
Einfluss totaler Nahrungskarenz auf Serumproteinkonzentrationen. (Effect of total fasting on serum protein concentrations.) Klin Wschr. 1977; 55: 525 – 531.
Schwandt P, Richter W, Fateh-Moghadam A
Wirkungen verschiedener Reduktionsdiäten bei Adipositas. Münch. med. Wschr. 1980; 122 (41): 1418 – 1420.
Weisweiler P, Schwandt P.
Lipoprotein and apolipoprotein changes in obesity after a short-term fast. Int J Obes. 1981; 5: 11 – 14.
Schwandt P, Weisweiler P
High-density lipoprotein subfractions after short term fast. Horm. Metab. Res. 1981; 13: 467 – 468.
Schwandt P
Gewichtsreduktion bei Adipositas: Mischkost – nicht Außenseiterdiäten. Münch. Med. Wschr. 1987; 129(20): 371.
Schwandt P
Adipositas als Gesundheitsrisiko. Münch. Med. Wschr. 1988; 130(42): 717.
Richter WO, Möhrle W, Schwandt P
Obesity and the erythocyte sedimentation rate. Ann Intern Med. 1988; 109: 928 – 929.
Ritter MM, Mohrle W, Richter WO, Schwandt P
No change of beta-endorphin plasma levels during hyperglycemic glucose clamping in obese patients and lean controls. Horm. Metab. Res. 1990; 22: 504 – 505.
Ritter MM, Schraudolph M, Richter WO, Herbert M, Wiebecke B, Schwandt P
Adipositas, Herzinsuffizienz und pulmonale Insuffizienz bei einer 26-jährigen Frau. Med. Klinik 1990; 85: 371 – 375.
Ritter MM, Sönnichsen AC, Mohrle W, Richter WO, Schwandt P.
Beta-endorphin plasma levels and their dependence on gender during an enteral glucose load in lean subjects as well as in obese patients before and after weight reduction. Int. J. Obes. 1991; 15: 421 – 427.
Ritter MM, Richter WO, Schwandt P
Increase of ß-endorphin serum levels by human corticotropinreleasing factor does not affect beta-cell function in overweight women. Horm. metabol. Res. 1992; 24: 349 – 350.
Sönnichsen AC, Richter WO, Schwandt P
Benefit from hypocaloric diet in obese men depends on the extent of weight-loss regarding cholesterol, and on a simultaneous change in body fat distribution regarding insulin sensitivity and glucose tolerance. Metabolism 1992; 41(9): 1035 – 1039.
Ritter MM, Richter WO, Möhrle W, Schwandt P
The unfavourable lipid constellation of obesity is correlated with impaired insulin sensitivity. Nutr Metab Cardiovasc Dis. 1994; 4: 16 – 19.
Richter WO, Geiss HC, Aleksic S, Schwandt P
Cardiac autonomic nerve function and insulin sensitivity in obese subjects. Int J Obes Relat Metab Disord.1996; 20: 966-969.
Donner MG, Schwandt P
Übergewicht belastet Blutdruck und Stoffwechsel. Fortschr. Med. SD 1999; 49-50: 37 – 41.
Geiss HC, Parhofer KG, Schwandt P
Parameters of childhood obesity and their relationship to cardiovascular risk factors in healthy prepubescent children. Int J Obes. 2001; 25: 830 – 837.
Can G, Schwandt P, Onat A, Hergenc G, Haas GM
Body fat, dyslipidemia, blood pressure and the effects of smoking in Germans and Turks. Turk J Med Sci 2009; 39(4): 579 – 589
DIABETES MELLITUS
Schwandt P, Richter W, Wilkening J
Chronic insulin overtreatment. Lancet 1979; 4: 261 – 262.
Schwandt P, Richter W
Chronische Insulinüberbehandlung bei Diabetikern im Erwachsenenalter. Dtsch. Med. Wschr. 1980; 105 (25): 892 – 894.
Weisweiler P, Drosner M, Schwandt P
Dietary effects on very low-density lipoproteins in type 2 (non-insulin-dependent) diabetes mellitus. Diabetologia 1982; 23: 101 – 103.
Weisweiler P, Merk W, Schwandt P
Analysis of serum lipoproteins in insulin-dependent (Type I) and noninsulin-dependent (Type II) Diabetes mellitus. Monogr. Atheroscler. 1985; 13: 104 – 110.
Weisweiler P, Schwandt P
Type 1 (insulin-dependent) versus type 2 (non-insulin-dependent) diabetes mellitus: Characterization of serum lipoprotein alterations. Eur. J. Clin. Invest. 1987; 17: 87 – 91.
Ritter MM, Richter WO, Schwandt P
Therapie der diabetischen Gangrän durch kontinuierliche subkutane Insulintherapie. Münch. Med. Wschr. 1988; 130(6): 62 – 64.
Richter WO, Ritter M, Schwandt P
Opoid peptides and diabetes mellitus in man. J. Endocrinol. Invest. 1989; 12 (Suppl. 4): 71 – 75.
Möhrle W, Richter WO, Schwandt P
Intensivierte kontrollierte Insulintherapie – Langzeiterfolge und Gründe für das Versagen dieses Therapiekonzeptes. Dtsch. med. Wschr. 1989; 114: 899 – 902.
Parhofer KG, Richter WO, Schwandt P
Apolipoprotein E phenotype frequency in type II diabetic patients with different forms of hyperlipoproteinemia. Horm. metabol. Res. 1990; 22: 589 – 594.
Schwandt P
Gastrointestinale Motilitätsstörungen beim Diabetes mellitus. Z gesamte Inn. Med. 1991; 46: 327 – 331.
Ritter MM, Richter WO; Lyko K, Schwandt P
Lp(a) serum concentrations and metabolic control. Diabetes Care. 1992; 15: 1441 – 1442.
Ritter MM, Richter WO, Leinsinger G, Kirsch CM, Schwandt P
Granulocytes and three-phase bone scintigraphy for differentiation of diabetic gangrene with and without osteomyelitis. Diabetes Care 1992; 15(8): 1014 – 1019.
Sönnichsen AC, Richter WO, Schwandt P
Abdominale Schmerzen, papulöses Exanthem, Gedächtnisstörungen und Polyneuropathie bei einem 50jährigen Patienten mit Diabetes mellitus. Internist 1992; 33: 834 – 837.
Ritter MM, Loscar M, Richter WO, Schwandt P
Lipoprotein(a) in diabetes mellitus. Clin. Chim. Acta 1993; 214: 45 – 54.
Geiss HC, Schwandt P, Parhofer KG
Influence of simvastatin on LDL subtypes in patients with heterozygous familial hypercholesterolemia and in patients with diabetes mellitus and mixed hyperlipo-proteinemia. Exp Clin Endocrinol Diabetes. 2002; 110: 182 – 187.
METABOLIC SYNDROME – INSULIN RESISTANCE
Vogeser M, Schwandt P, Haas GM, Broedl UC, Lehrke M, Parhofer KG
BMI and Hyperinsulinemia in children. Clin Biochem. 2009; 42: 1427 – 1430
Schwandt P, Kelishadi R, Haas GM
Ethnic Disparities of the Metabolic Syndrome in Population-Based Samples of German and Iranian Adolescents. Metabolic Syndrome and Related Disorders 2010; 8 (2): 95 – 98
Schwandt P, Kelishadi R, Ribeiro RQC, Haas GM, Poursafa P
A three-country study on the components of the metabolic syndrome in youths: The BIG Study. Intern Journal of Pediatric Obesity 2010; 5: 334 – 341
CLINICAL CHEMISTRY
Weisweiler P, Schwandt P
Determination of human apolipoproteins A-I, B, and E by laser nephelometry. J. Clin. Chem. Clin. Biochem. 1984; 22: 113 – 118.
Marschner J, Bottermann P, Erhardt H, Linke R, Löffler G, Maier V, Schwandt P, Vogt W, Scriba PC
Group experiments on the radioimmunological insulin determination. Horm. Metabol. Res. 1974; 6: 293 – 296.
Schwandt P, Weisweiler P
Determination of cholesterol and phospholipid concentrations in high-density lipoproteins by heparin-manganese chloride precipitation. Clin. Chim. Acta 1979; 95: 395 – 399.
Weisweiler P, Schottdorf B, Schwandt P
Cholesterol in high-density lipoproteins: A comparison between dextran sulfate-magnesium-chloride precipitation and preparative ultracentrifugation. J Clin Chem Clin Biochem 1979; 17: 773 – 775.
Weisweiler P, Sperl B, Schwandt P
Determination of High-Density Lipoproteins: Comparison of HDL-Cholesterol, HDL-Phospholipids, and HDL-Apolipoprotein A-I. Clinical Chemistry 1981; 27 (2): 348.
Schwandt P, Richter WO, Weisweiler P
Separation of apolipoprotein B subfractions by high performance gel permeation chromatography. Clin. Chim. Acta 1986; 157: 249 – 252.
Weisweiler P, Friedl C, Schwandt P
Isolation and Quantification of apolipoproteins C-I, C-II, and C-III0-2 in very-low-density lipoproteins by “High-Performance” anion exchange chromatography. Clin. Chem., 1986; 32: 992 – 994.
Geiss HC, Ritter MM, Richter WO, Schwandt P
Determination of apolipoprotein(a) isoforms by sodium dodecyl sulfatepolyacrylamide electrophoresis and immunoblotting. Anal Biochem. 1993; 15: 168 – 169.
CLINICAL PHARMACOLOGY
Schwandt P
Absorbable and not absorbable Hypolipidemic Drugs. The 14th international Symposium on Clinical Pharmacology, Tokyo, 1976, Sonderdruck Abstract S. 335 – 345.
Schwandt P
Wechselwirkungen bei Behandlung mit Hypolipidämika und Urikostatika. Therapiewoche 1978; 28: 3182 – 3184.
Schwandt P.
Drug interactions and side effects of hypolipidemic drugs. Int. J. Clin. Pharmacol. 1979; 17 (8): 351 – 356.
Schwandt P
Problems in testing hypolipidemic agents in phase II. Int J Clin Pharmacol Ther Toxicol. 1980; 18: 370 – 373.
Schwandt P
Nebenwirkungen und Arzneimittelwechselwirkungen lipidsenkender Pharmaka. Münch Med Wschr. 1980; 122: 474 – 476.
Schwandt P
Introductory report: Clofibrate Analogs. Therapeutic Selectivity and Risk. Benefit Assessment of hypolipidemic drugs. New York 1982.
Schwandt P
Les hypolipémiants dans la prévention et dans le traitement de l’athérosclerose. Gazette Medicale de France 1982; 3e Colloque International, Dijon 13.-14. Mars: 27 – 34.
Schwandt P
Antilipidämika. Klinik und Therapie der Nebenwirkungen 1984; 864 – 873.
Schwandt P
Antazida. Klinik und Therapie der Nebenwirkungen 1984; 874 – 880.
Merk W, Graben N, Hartmann H, Nikolaus C, Schlierf G, Schwandt P
Serum levels of free non-protein bound clofibrinic acid after single dosing to patients with impaired renal functions of various degrees – a multicenter study. Int. J. Clin. Pharmacol. Ther. Toxicol. 1987; 25: 59 – 62.
Middeke M, Weisweiler P, Schwandt P, Holzgreve H
Serum lipoproteins during anthihypertensive therapy with ß-blockers and diuretics: a controlled long-term comparative trial. Clin. Cardiol. 1987; 10: 94 – 98.
Richter WO, Schwandt P
Serious side effect of nifedipine. Arch Intern Med. 1987; 147: 1850.
Middeke M, Richter WO, Schwandt P, Beck B, Holzgreve H
Normalization of lipid metabolism after withdrawal from antihypertensive long-term therapy with beta blockers and diuretics. Atherosclerosis 1990; 10: 145 – 147.
Schwandt P
Fibrates and triglycerides metabolism. Biomedical Division. Drugs affecting lipid metabolism X, Gotto Jr. AM and Smith LC eds. Abstract S. 229 – 235.
Schwandt P
Fibrates and triglyceride metabolism. Eur J Clin Pharmacol. 1991; 40(Suppl.1): 41 – 43.
Richter WO, Jacob BG, Schwandt P
Interaction between fibre and lovastatin. Lancet 1991; 338 (8768): 706.
Richter WO, Jacob BG, Schwandt P
Comparative effects of two HMG-CoA reductase inhibitors (Lovastatin and Pravastatin) on serum lipids and lipoproteins. Int. J. Tiss. Reac. XIII(2): 107 – 110.
Ritter MM, Richter WO, Schwandt P
Metabolische Konsequenzen einer antihypertensiven Langzeitbehandlung mit Co-dergocrinmesilat / Nifedipin im hohen Lebensalter. Arzneim.-Forsch/Drug Res. 1992; 42(I): 311 – 313.
Ritter MM, Richter WO, Schwandt P
Die Auswirkungen von Betablockern auf den Lipoproteinstoffwechsel. Fortschr. Med. 1992; 28: 507/47 – 510/50.
Jacob BG, Richter WO, Schwandt P
Einfluss dreier antihypertensiver Wirkgruppen auf den Fettstoffwechsel. Fortschr. Med. 1993; 111(8): 38/126 – 42/130.
Möhrle W, Sühler K, Richter WO, Schwandt P
Lipidmetabolismus – Einfluss von Kardiaka und ACE-Hemmern. Fortschr. Med. 1993; 111(5): 61/45 – 48/64.
Otto C, Pschierer V, Schwandt P, Richter WO
Effect of gemfibrozil treatment on plasma fibrinogen levels in patients with familial hypertriglyceridaemia. Blood Coagulation and Fibrinolysis 1994; 5(Suppl.2): 26 – 27.
Schwandt P, Elsäßer R, Schmidt C, Gertz B, Heil M, Augustin J, Seibel K
Safety and efficacy of lifibrol upon four-week administration to patients with primary hypercholesterolaemia. Eur. J. Clin. Pharmacol. 1994 ; 47 : 133 – 138.
Middeke M, Richter WO, Schwandt P, Holzgreve H
The effect of antihypertensive combination therapy on lipid and glucose matabolism: hydrochlorothiazide plus sotalol vs. hydrochlorothiazide plus captopril. Int J Clin Pharmacol and Therapeutics 1997; 35(6): 231 – 234.
NUTRITION
Schwandt P, Richter WO, Weisweiler P
Soybean protein and serum cholesterol. Atherosclerosis 1981; 40: 371 – 372.
Richter WO, Weisweiler P, Schwandt P
Beeinflussung der Serumlipoproteine durch Sojabohneneiweiß. Münch. med. Wschr. 1981; 123: 1755 – 1756.
Schwandt P, Janetschek P, Weisweiler P
High density lipoproteins unaffected by dietary fat modification. Atherosclerosis. 1982; 44: 9 – 17.
Richter WO, Schwandt P
Ballaststoffe bei Hyperlipoproteinämien. Münch Med. Wschr. 1983; 125 Nr. 19: 407 – 410.
Weisweiler P, Drosner M, Janetschek P, Schwandt P
Changes in very low and low density lipoproteins with dietary fat modification. Atherosclerosis. 1983; 49: 325 – 332.
Weisweiler P, Janetschek P, Schwandt P
Apolipoprotein E enriched VLDL and their relations to fat intake. Latent Dyslipoproteinemias and Atherosclerosis 1684: 297 – 304.
Weisweiler P, Janetschek P, Schwandt P
Influence of polyunsaturated fats and fat restriction on serum lipoproteins in humans. Metabolism. 1985; 34: 83 – 87.
Weisweiler P, Janetschek P, Schwandt P.
Fat restriction alters the composition of apolipoprotein B-100 containing very low-density lipoproteins in humans. Am. J. Clin. Nutr. 1986; 43: 903 – 909.
Schwandt P
Therapeutische Effekte diätischer Maßnahmen bei Patienten mit Hyperlipoproteinämien. Akt. Ernährung 1987; 12: 7 – 10.
Ritter MM, Schwandt P
Eikosanoide – biologisch wichtige Produkte ungesättigter Fettsäuren. Hämostaseologie 1987; 7: 88 – 93.
Schwandt P, Richter WO
Brief an die Herausgeber – Stellungnahme zur Originalarbeit: Lutz W: Atherosklerose und Krebs – Fette oder Kohlenhydrate? Wien. Klin. Wochenschr. 1989; 101: 429 – 433.
Schwandt P
Wirkungen der Kohlenhydrate im Fettstoffwechsel des Gesunden. Ernährungs-Umschau 1989; 36(5): 178 – 180.
Schwandt P
Fat modified diet in the prevention of cardiovascular disease. Recommendations and Guidelines. Acta Cardiologica 1989; Vo. XLIV, 6: S. 490 – 492.
Schwandt P
Nahrungsfette und Atherosklerose. Verhandlungen der Deutschen Gesellschaft für Innere Medizin. 97. Kongress, Wiesbaden 1991. 227 – 238.
Schraudolph M, Richter WO, Schwandt P
Ernährungstherapie der Dyslipoproteinämien. Der Bayerische Internist 1990; 6: 24 – 29.
Otto C, Sönnichsen AC, Ritter MM, Richter WO, Schwandt P
Influence of fiber, xylitol and fructose in enteral formulas on glucose and lipid metabolism in normal subjects. Clin. Invest. 1993; 71: 290 – 293.
Mussner MJ, Parhofer KG, Von Bergmann K, Schwandt P, Broedl U, Otto C
Effects of phytosterol ester-enriched margarine on plasma lipoproteins in mild to moderate hypercholestrolemia are related to basal cholesterol and fat intake. Metabolism 2002; 51: 189 – 194.
Schwandt P, Haas GM, Bertsch T
Nutrition and Cardiovascular Risk Factor in Four Age Groups of Female Individuals: The PEP Family Heart Study. Intern J Prev Med. 2010; 1 (2): 104 – 110
PHYSICAL ACTIVITY
Weisweiler P, Backs C, Hüllemann K, Schwandt P
Effekte eines intensiven Ausdauertrainings auf die Serumlipoproteine von Männern und Frauen. Herz-Kreislauf 1985; 2: 82 – 85.
LIFESTYLE
Schwandt P, Geiss HC, Ritter MM, Üblacker C, Parhofer KG, Otto C, Laubach E, Donner MG, Haas GM, Richter WO
The prevention education program (PEP). A prospective study of the efficacy of family-oriented life style modification in the reduction of cardiovascular risk and disease: design and baseline data. J Clin Epidemiol. 1999; 52: 791 – 800. (261)
Tröbs M, Renner T, Scherer G, Heller WD, Geiss HC, Wolfram G, Haas GM, Schwandt P
Nutrition, Antioxidants, and risk factor profile of nonsmokers, passive smokers and smokers of the Prevention Education Program (PEP) in Nuremberg, Germany. Prev Med. 2002; 34: 600 – 607.
Schwandt P, Liepold E, Bertsch T, Haas GM
Lifestyle, Cardiovascular Drugs an dRisk Factors in Younger and Elder Adults: The PEP Family Heart Study. Int J Prev Med. 2010; 1 (1): 56 – 61.
Schwandt P, Haas GM, Liepold E
Lifestyle and cardiovascular risk factors in 2001 child-parent pairs: The PEP Family Heart Study. Atherosclerosis 2010; 213: 642-648.
ATHEROSCLEROSIS
Schwandt P
Zur Prävention der Atherosklerose. Münch. Med. Wschr. 1988; 130(14): 241 – 243.
Study Group, European Atherosclerosis Society
The recognition and management of hyperlipidaemia in adults: A policy statement of the European Atherosclerosis Society. Eur Heart Journal 1988: 9: 571 – 600.
Schwandt P
Triglyceride-Rich Lipoproteins and Atherosclerosis. Redefining Risk Factors for Coronary Heart Disease: The Benefit of Regulating Lipoproteins, Symposium 1989, Abstract S. 38 – 41.
Schwandt P
Störungen des postprandialen Lipidstoffwechsels – Klinik Triglyceridreiche Lipoproteine als Risikofaktor für die Atherosklerose. Klin. Wschr. 1990; 68 (Suppl. XXII): 54 – 58.
Schwandt P
The triglyceride controversy: a review of the data. Eur Heart J 1990; 11(Suppl.H): 38 – 43.
Schwandt P
Wie sinnvoll ist die Therapie der Hyperlipidämie und der Arteriosklerose im höheren Lebensalter? Ernährungs-Umschau 1993; 40(7): 288 – 290.
Donner MG, Klein GK, Mathes PB, Schwandt P, Richter WO
Plasma total homocysteine levels in patients with early-onset coronary heart disease and a low cardiovascular risk profile. Metabolism 1998; 47: 273 – 279.
Liepold E, Schwandt P
„PEP“ – Familienprogramm gegen KHK-Risiken. Ernährungs-Umschau1999; 46: 143 – 145.
Schwandt P
KHK-Primärprävention in der Praxis. Wie erkenne und definiere ich einen Risikopatienten? Fortschr. Med. SD 1999; 141: 726 – 728.
Schwandt P, Betteridge J, Erkelens W, Mancini M, Ochsenhirt B, Parhofer KG, Paulweber B, Saner H, Volta SD
The patient with CHD: how should we translate international gudelines into clinical practice? Nutr Metab Cardiovasc Dis. 2000; 10: 79 – 84.
Otto C, Ritter MM, Richter WO, Minkenberg R, Schwandt P
Hemorrheologic abnormalities in defined primary dyslipoproteinemias with both high and low atherosclerotic risks. Metabolism. 2001; 50: 166 – 170.
Schwandt P, Haas GM
Sekundärprävention kardiovaskulärer Erkrankungen. Was raten Sie Ihren Patienten nach Herzinfarkt?
MMW Fortschr Med. 2002; 31/32: 27 – 28. (290)
Erkelens DW, Schwandt P
Modern Aspects of Atherosclerosis and Treatment of Lipid Disorders. Atherosklerosis Suppl. 3; 2002: 1 – 2.
Schwandt P
The importance of Reaching Lipid Targets: Statins and the Prevention of Atherosclerosis. Int J Clin Pract 2003; 57: 396 – 404.
Schwandt P, Brady AJB
Achieving lipid goals in Europe: how large is the treatment gap? Expert Rev. Cardiovasc. Ther. 2004; 2(3), 431 – 449.
Haas GM, Parhofer KG, Schwandt P
Prevalence of Cardiovascular Disease Risk Factors in Migrants Participating in the PEP Family Heart Study, Nuremberg. Int J Prev Med. 2010; 1 (1): 19 – 28
EPIDEMIOLOGY
Assmann G, Berg A, Breithardt G, Gleichmann U, Halhuber M, Keil U, Kochsick K, Kruse-Jarres J, Lichtlen P, Schlierf G, Schwandt P, Weidemann H, Wisser H
Nationale Cholesterin-Initiative. SD Dtsch. Ärzteblatt – Ärztliche Mitteilungen 1990: 1 – 20.
Richter WO, Möhrle W, Schwandt P
Cholesterinwerte in der Bayerischen Bevölkerung. Münch. med. Wschr. 1992; 134: 361 – 364.
Schwandt P, Richter WO, Möhrle W
Bavarian Cholesterol Screening Project: Cholesterol and Other Risk Factors in the Elderly. Workshop, Washington DC, 1990: 53 – 60.
Richter V, Rassoul F, Reuter W, Otto J, Richter WO, Schwandt P, Rotzsch W
Cholesterin-Screening auf Bevölkerungsebene in Leipzig im Rahmen der bayerischen Cholesterinaktion. Z. gesamte Inn. Med. 1992; 47: 359 – 361.
Richter WO, Möhrle W, Schwandt P
Prevalence of High Plasma Cholesterol Levels and other Risk Factors for Coronary Artery Disease among the Bavarian Population. Treatment of severe Dyslipoproteinemia in the Prevention of CHD 4, 1993. – 4th Int. Symposium, Munich 1992; 1 – 6.
Schwandt P, Richter WO, Sönnichsen C
Bavarian Cholesterol Screening Project (BCSP). Cardiovascular Disease 2, London 1995: 353 – 357.
Richter WO, Sönnichsen AC, Schwandt P
Results and efficacy of public screening for hypercholesterolemia: the Bavarian Cholesterol Screening Project. J Clin Epidemol. 1995; 48: 1307 – 1317.
Richter WO, Schwandt P
Lipid-lowering therapy after myocardial infarction: the Bavarian Cholesterol Screening Project. JAMA 1998; 280: 603 – 604.
Öhrig E, Geiss HC, Haas GM, Schwandt P
The Prevention Education Program (PEP) Nuremberg: design and baseline data of a family oriented intervention study. Int J Obesity 2001; 25: 51 – 54.
Schwandt P, Geiss HC, Haas GM
Global Cardiovascular risk in children and their families: The Prevention Education Program (PEP) Nürnberg. Nutr Metab Cardiovasc Dis. 2001; Suppl 5: 35 – 39.
Schwandt P, Bischoff-Ferrari HA, Staehelin HB, Haas GM
Cardiovascular risk screening in school children predicts risk in parents. Atherosclerosis 2009: 250: 626 – 631
ANTHROPOMETRY
Sönnichsen AC, Richter WO, Schwandt P
Body fat distribution and serum lipoproteins in relation to age and body weight. Clin. Chim. Acta 1991; 202: 133 – 140.
Sönnichsen AC, Ritter MM, Möhrle W, Richter WO, Schwandt P
The waist-to-hip ratio corrected for body mass index is related to serum triglycerides and high-density lipoprotein cholesterol but not to parameters of glucose metabolism in healthy premenopausal women. Clin. Invest. 1993; 71: 913 – 917.
Kelishadi R, Schwandt P, Haas GM, Hosseini M, Mirmoghtadaee P
Reference curves of anthropometric indices and serum lipid profiles in representative samples of Asian and European children. Arch Med Sci 2008; 3: 329 – 335
Schwandt P, Kelishadi R, Haas GM
First reference curves of waist circumference for German children in comparison to international values: the PEP Family Heart Study. World J Pediatr 2008; 4 (4): 259 – 266
Schwandt P, Bertsch T, Haas GM
Anthropometric screening for silent cardiovascular risk factors in adolescents: The PEP Family Heart Study. Atherosclerosis 2010; 211: 667 – 671
Haas GM, Liepold E, Schwandt P
Percentile curves for fat pattering in German adolescents. World J Pediatr 2011; 7 (1): 16 – 23.
Schwandt P, Scholze JE, Bertsch T, Liepold E, Has GM
Blood Pressure Percentiles in 22,051 German Children and
Adolescents: The PEP Family Heart Study
Am J Hypertens (2015) 28 (5): 672-679 first published online November 19, 2014
Response to „Right Analysis-Wrong Conclusion: Obese Youth With Higher BP Are at Risk for Target Organ Damage“.
Schwandt P1,4, Scholze JE2, Bertsch T3, Liepold E4, Haas GM4.
Am J Hypertens. 2015 Aug;28(8):1072-3.
Why stigmatize overweight young people as hypertensive by using normative percentiles from non-overweight youth?
Schwandt P1,2, Haas GM2.
Int J Obes (Lond). 2015 ;39:1508.
Low Birth weight as a Predictor of Cardiovascular Risk Factors in childhood and adolescence? The PEP Family Heart Study
Haas GM, Liepold E, Schwandt P
IJPVM in press
Literaturverzeichnis in Auszügen
1. Schwandt P, Janetschek P, Weisweiler P. High density lipoproteins unaffected by dietary fat modification. Atherosclerosis. 1982; 44: 9 – 17
2. Weisweiler P, Drosner M, Janetschek P, Schwandt P. Changes in very low and low density lipoproteins with dietary fat modification. Atherosclerosis. 1983; 49: 325-332
3. Schwandt P, Richter WO, Möhrle W. Bavarian Cholesterol Screening Project: Cholesterol and Other Risk Factors in the Elderly. Workshop, Washington DC, 1990: 53 – 60
4.Schwandt P, Richter WC, Möhrle W. Primary health care and CHD prevention: The German experience. Royal Society of Medicine Services Limited 1991, International Congress and Symposium Series No. 177; 21 – 26
5. Richter WO, Möhrle W, Schwandt P. Cholesterinwerte in der Bayerischen Bevölkerung. Münch. med. Wschr. 1992; 134: 361 – 364
6. Schwandt P, Geiss HC, Ritter MM, Üblacker C, Parhofer KG, Otto C, Laubach E, Donner MG, Haas GM, Richter WO. The prevention education program (PEP). A prospective study of the efficacy of family-oriented life style modification in the reduction of cardiovascular risk and disease: design and baseline data. J Clin Epidemiol. 1999; 52: 791 – 800
7. Geiß HC, Öhrig E, Haas G-M, Schwandt P. Familien orientierte Primärprävention:
Das Präventions-Erziehungs- Programm Nürnberg (PEP). Bayerisches Ärzteblatt, 2000;1:6-7
8. Kannel WB, Cupples LA, Ramaswami R, Stokes III J, Kreger BE, Higgins M. Regional obesity and risk of cardiovascular disease: The Framingham Study. J Clin Epidemiol 1991; 44:183-190.
9. Richter WO, Sönnichsen AC, Schwandt P. Results and efficacy of public screening for hypercholesterolemia: the Bavarian Cholesterol Screening Project. J Clin Epidemiol. 1995; 48: 1307 – 1317
10. Richter WO, Schwandt P. Lipid-lowering therapy after myocardial infarction: the Bavarian Cholesterol Screening Project.
JAMA. 1998; 280: 603 – 604
11. Schwandt P, Bertsch T, Haas GM. Anthropometric screening for silent cardiovascular risk factors in adolescents: The PEP Family Heart Study. Atherosclerosis 2010; 211: 667 – 671.
12. Schwandt P, Bertsch T, Haas GM. Body fat and serum lipids in first graders throughout 10 years: The PEP Family Heart Study. Atherosclerosis, Jun 2012 Suppl
13. Schwandt P, Bertsch T, Liepold E, Haas GM. 5 years follow-up of cardiovascular risk factors and lifestyle components in children. Atherosclerosis Supplements 12, no 1(2011) 1-11.
14. Geiss HC, Parhofer KG, Schwandt P.Parameters of childhood obesity and their relationship to cardiovascular risk factors in healthy prepubescent children. Int J Obes Relat Metab Disord. 2000; 25: 830 – 837
15.Sönnichsen AC, Richter WO, Schwandt P. Body fat distribution and serum lipoproteins in relation to age and body weight. Clin. Chim. Acta 1991; 202: 133 – 140.
16. Schwandt P and Gerda-Maria Haas. Reference Curves of Waist Circumference in Children and Adolescents. 2012 , Part 13: 1405 -1412. DOI: 10.1007/978-1-1788-1_85 in: Handbook of Anthropometry, Preedy Victor R. (Ed.)
17. Haas GM, Liepold E, Schwandt P. Predicting Cardiovascular Risk Factors by Different Body Fat Patterns in 3850 German Children: the PEP Family Heart Study. Int J Prev Med 2011; Jan. 2(1): 15 -19
18. Schwandt P, von Eckardstein A, Haas GM .Percentiles of percentage body fat in German children and adolescents: an international comparison .Int J Prev Med 2012; 3, 846 – 852
19. Kelishadi R, Schwandt P, Hosseini M, Haas GM. An anthropometric comparison between 3-11-year-old
children of a Western and a non-Western population. Atherosclerosis Supplement, 9/1; 2008 : 223
20. Kelishadi R, Schwandt P, Haas GM, Hosseini M, Mirmoghtadaee P. Reference curves of anthropometric indices and serum lipid profiles in representative samples of Asian and European children. Arch Med Sci 2008; 4: 329 – 335
21. Haas GM, Bertsch T, Schwandt P. Are the ratio triglycerides to high density lipoprotein cholesterol (TG/HDL c) as indicator for insulin resistance (IR) affected by age? The PEP Family Heart Study.European Heart Journal (2008) 29 (Abstract Supplement), 593
22. Haas GM, Liepold E & Schwandt P. (2008). Hypertension in Turkish and German first graders participating in the PEP Family Heart Study. Atherosclerosis 2008; Suppl.; 9: 95
23. Schwandt P, Scholze JE, Bertsch T, Liepold E, Haas GM.Blood pressure percentiles in 22,051 German children and adolescents: The PEP Family Heart Study. Am J Hypertenssion 2015; 28:672-679
24. Schwandt P, Liepold E, Haas GM. Diet and Lifestyle Modification Starting in Childhood together with the Whole Family: Is this realistic? Seminar, Universita di Milano, Nutrition Foundation of Italy, Mailand 10. Juni 2003
25. Haas GM, Liepold E, Schwandt P. Was essen übergewichtige Erstklässler? Diabetes und Stoffwechsel 2004; 13: 8 – 9
26. Schwandt P, Bertsch T, Liepold E, Haas GM. Nutrition and cardiovascular risk factors in children: the PEP Family Heart Study. Europ Heart J, 2011 (suppl.) p.721
27. Haas GM, Liepold E, Schwandt P. Ernährung und Sport. Vortrag zum 40. Jahrestag der Deutschen Diabetes-Gesellschaft, Berlin, 4. – 7. Mai 2005
28. Schwandt P, Bertsch T, Haas GM. Sustained lifestyle advice and cardiovascular risk factors in 687 biological child-parent pairs: The PEP Family Heart Study. Atherosclerosis 2011; 219 (2): 937 – 945
29. Schwandt P, Bischoff -Ferrari HA, Staehelin HB, Haas GM. Cardiovascular risk screening in school children predicts risk in parents. Atherosclerosis 2009: 250: 626 – 631
30. Schwandt P, Liepold E, Hass GM. Cardiovascular Risk Factors in 1.202 Families in Nürnberg (9th PEP – Survey) Arteriosklerose – Präventions – Institut München, Germany. Ann Nutr Metab 2003; 47: 229 – 254
31. Schwandt P, Liepold E, Bertsch T, Gallert K
Lifestyle and risk factors for cardiovascular disease in the elderly.
Journal of Clinical Lipidology, Volume 1 (5) 2007 Page 425
32. Haas GM, Liepold E, Schwand t P. Socio-economic risk factors in the community-based PEP Family Heart Study Vortrag beim ESC-Congress 2011 in Paris. Eur Heart J, Aug. 2011 (suppl.) p.673
32. Haas GM, Liepold E, Schwandt P. CVD risk factors in 1731 children associated with their birth weight and age of their mothers at delivery: the PEP Family Heart Study. Atherosclerosis, Jun 2012 Suppl.
33. Schwandt P, Kelishadi R, Haas GM. First reference curves of waist circumference for German children in comparison to international values: the PEP Family Heart Study. World J Pediatr 2008; 4(4): 259 – 266
34. Schwandt P, Kelishadi R, Ribeiro RQC, Haas GM, Poursafa P.A three-country study on the components of the metabolic syndrome in youths: The BIG Study. Intern Journal of Pediatric Obesity 2010; 5: 334 – 341
35. Haas GM, Liepold E, Schwandt P. Age- and gender-specific Waist circumference percentiles in German and Turkish children participating in the PEP Family Heart Study
Journal of Clinical Lipidology, Volume 1 (5) 2007 Page 360
36. Haas GM, Onat A, Agirbasli M, Schwandt P. CVD risk factors and lifestyle in Turkish migrants and residents in Nuremberg and Istanbul: The PEP Family Heart Study. Atherosclerosis Supplement 2009, Vol. 10, Issue 2, Abstract: P1359
37. Xi B, Zong X, Kelishadi R et al. Establishing international blood pressure references among non-overweight children and adolescents aged 6 to 17 years. Circulation 2016
38 Schwandt P, Haas GM..Why stigmatize overweight young people as hypertensive by using normative percentiles from non-overweight youth?
Int J Obes (Lond). 2015 Oct;39(10):1508. doi: 10.1038/ijo.2015.150. Epub 2015 Aug 12. No abstract available.
39 Schwandt P, Scholze JE, Bertsch T, Ecotroph EL, Haas GM..Response to „Right Analysis-Wrong Conclusion: Obese Youth With Higher BP Are at Risk for Target Organ Damage“.
Am J Hypertens. 2015 Aug;28(8):1072-3. doi: 10.1093/ajh/hpv085. Epub 2015 Jun 4. No abstract available.
40. Haas GM, Liepold E, Schwandt P.Trends im Ernährungsverhalten großstädtischer Erstklässler in einem Zeitraum von 5 Jahren
Diabetes und Stoffwechsel, Mai 2016
41 Schwandt P, Bertsch T, Haas GM..Nachhaltigkeit von HEALTHY LIFESTYLE
Diabetes und Stoffwechsel, Mai 2016
42. Peter Schwandt, Evelyn Liepold , Monika Heinzel-Gutenbrunner ,Thomas Bertsch , Gerda-Maria Haas. SUSTAINED NUTRITIONAL COUNSELING IMPROVES DIETARY INTAKE IN PARENTS AND THEIR CHILDREN OVER 5 YEARS: THE PEP FAMILY HEART STUDY ATHEROSCLEROSIS, May 2016, Suppl.
43. Gerda-Maria Haas, Evelyn Liepold, Thomas Bertsch , Peter Schwandt, MD, PhD.
STRONGLY INCREASING PREVALENCE OF HYPERTENSION BY INCREASING OVERWEIGHT IN CHILDREN AND ADOLESCENTS: THE PEP FAMILY HEART STUDY
ATHEROSCLEROSIS, May 2016
44. Thomas Bertsch , Gerda-Maria Haas, Evelyn Liepold, Peter Schwandt. ASSOCIATIONS OF TRIGLYCERIDES WITH PERCENT BODY FAT IN ADOLESCENTS: THE PEP FAMILY
HEART STUDY
ATHEROSCLEROSIS, May 2016
45. Peter Schwandt and Gerda-Maria Haas
Is the ratio waist circumference to height (WHtR) of 0.5 a universal measure for abdominal adiposity in children and adolescents?
Int J Obes (Lond). (2016) 40, 1141-1142
46. Schwandt P, Liepold E, Bertsch T, Haas GM
Sustained dietary counseling throughout 3 years improves dietary intake and cardiovascular risk factors in adults: The PEP Family Heart Study
European Heart Journal
Volume 37, Issue suppl_1,
August 2016 p.347/ 48 P 2721
47. Schwandt P, Liepold E, Bertsch T, Haas GM
Severely obese children and adolescents are at substantially higher cardiovascular risk: The PEP Family Heart Study
European Heart Journal
Volume 37, Issue suppl_1,
August 2016 p. 1335 P 6400
48. Schwandt P, Liepold E, Bertsch T, Haas GM
What do we learn from the family-based CVD risk factor prevention project PEP about lipigs and blood pressure?
International Symposium: Prevention models of obesity and
cardiovascular diseases November 11.-12.2016 Vienna (Austria)
2017:
Aufnahme der PEP-Ernährungs-Referenzwerte in das
Centre for Evidence-based Health Care
Department of Global Health
Faculty of Medicine and Health Sciences
Stellenbosch University
PO Box 241, Cape Town | 8000
Francie van Zijl Drive | Tygerberg, 7505
South Africa | Suid-Afrika
Tel: +27 21 938 9886
Email | E-pos: cenaude@sun.ac.za
The Centre for Evidence-based Health Care, Stellenbosch University is the joint host of:
50. Schwandt P, Haas GM
What do we learn from the PEP Family Heart Study about lifestyle-change, blood pressure and lipids in children and parents?. 2018 IJPM in press